Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

Expert
Prof. Diamant Thaçi, University of Lübeck, Germany
Conference
EADV 2019
Trial
ESPRIT

An analysis of registry data showed that patients with moderate-to-severe psoriasis treated with adalimumab had a 58% lower standardised mortality rate compared with the general population [1].

ESPRIT is an ongoing international, prospective, observational registry evaluating the long-term safety and effectiveness of the TNF blocker adalimumab in adults with moderate-to-severe chronic plaque psoriasis under real-world conditions. Ten-year data was analysed from 6,014 psoriasis patients with collectively 28,161 person-years on adalimumab in routine clinical practice.

“You may not believe it if someone tells you that you, as a dermatologist, can save patient lives by controlling psoriasis,” said Prof. Diamant Thaçi (University of Lübeck, Germany). Yet, this was exactly what the data showed: the standardised mortality ratio in participants in the ESPRIT registry was 58% lower than expected. ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on